These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25139313)

  • 21. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH; Chang CH; Gagne JJ; Hsu CL; Lai MS
    Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA.
    Cohen JS; Miles MC; Donohue JF; Ohar JA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():785-97. PubMed ID: 27143870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM; Beier J
    Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indacaterol for chronic obstructive pulmonary disease (COPD).
    Cazzola M; Proietto A; Matera MG
    Drugs Today (Barc); 2010 Mar; 46(3):139-50. PubMed ID: 20467588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indacaterol. A long-acting beta-2 agonist, no advantages in COPD.
    Prescrire Int; 2011 Sep; 20(119):201-5. PubMed ID: 21954512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ▼Olodaterol--another LABA for COPD.
    Drug Ther Bull; 2015 Apr; 53(4):42-5. PubMed ID: 25858815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Drug Saf; 2016 Jun; 39(6):501-8. PubMed ID: 26924197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indacaterol: a novel long-acting β(2) -agonist.
    Ray SM; McMillen JC; Treadway SA; Helmer RS; Franks AS
    Pharmacotherapy; 2012 May; 32(5):456-74. PubMed ID: 22499359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology and Therapeutics of Bronchodilators Revisited.
    Matera MG; Page CP; Calzetta L; Rogliani P; Cazzola M
    Pharmacol Rev; 2020 Jan; 72(1):218-252. PubMed ID: 31848208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
    Mroz RM; Minarowski L; Chyczewska E
    Adv Exp Med Biol; 2013; 756():23-8. PubMed ID: 22836615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
    Wang J; Nie B; Xiong W; Xu Y
    J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mastrodicasa MA; Droege CA; Mulhall AM; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):161-174. PubMed ID: 28004591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
    Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common lung conditions: chronic obstructive pulmonary disease.
    Delzell JE
    FP Essent; 2013 Jun; 409():23-31. PubMed ID: 23767419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.